RXi Pharmaceuticals Corp. (NASDAQ:RXII) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.34) EPS for the quarter, meeting the consensus estimate of ($0.34). During the same quarter in the previous year, the firm posted ($0.40) EPS.

RXi Pharmaceuticals Corp. (NASDAQ:RXII) opened at 1.02 on Thursday. The stock’s market cap is $6.69 million. The company’s 50-day moving average is $1.43 and its 200 day moving average is $2.06. RXi Pharmaceuticals Corp. has a 52 week low of $0.94 and a 52 week high of $4.46.

Earnings History for RXi Pharmaceuticals Corp. (NASDAQ:RXII)

Separately, Zacks Investment Research cut shares of RXi Pharmaceuticals Corp. from a “buy” rating to a “hold” rating in a research note on Friday, July 15th.

RXi Pharmaceuticals Corp. Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

5 Day Chart for NASDAQ:RXII

Receive News & Stock Ratings for RXi Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corp. and related stocks with our FREE daily email newsletter.